相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
Nikolaus Marx et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer
A. S. Abdelmoneim et al.
DIABETES OBESITY & METABOLISM (2015)
Mortality risk among sulfonylureas: a systematic review and network meta-analysis
Scot H. Simpson et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?
Jennifer C. Stone et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2015)
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial
Julio Rosenstock et al.
DIABETES & VASCULAR DISEASE RESEARCH (2013)
Association of sulphonylurea treatment with all-cause and cardiovascular mortality: A systematic review and meta-analysis of observational studies
Thomas Forst et al.
DIABETES & VASCULAR DISEASE RESEARCH (2013)
Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis
O. J. Phung et al.
DIABETIC MEDICINE (2013)
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
Linda G. Mellbin et al.
EUROPEAN HEART JOURNAL (2013)
Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials
Matteo Monami et al.
ADVANCES IN THERAPY (2012)
The TOSCA.IT Trial: A Study Designed to Evaluate the Effect of Pioglitazone Versus Sulfonylureas on Cardiovascular Disease in Type 2 Diabetes
Olga Vaccaro et al.
DIABETES CARE (2012)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Rosiglitazone Revisited An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality
Steven E. Nissen et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
A Summary of the ADVANCE Trial
Simon R. Heller
DIABETES CARE (2009)
Cardiovascular Outcomes in Trials of Oral Diabetes Medications - A Systematic Review
Elizabeth Selvin et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies
Ajay D. Rao et al.
DIABETES CARE (2008)
Vascular disease and diabetes: is hypoglycaemia an aggravating factor?
Rohana J. Wright et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2008)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A systematic review and meta-analysis of hypoglycemia and cardiovascular event - A comparison of glyburide with other secretagogues and with insulin
Azim S. Gangji et al.
DIABETES CARE (2007)
Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies
R Huxley et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide
G Belcher et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2004)
Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes
R Scognamiglio et al.
DIABETES (2002)
Mortality and causes of death in the WHO multinational study of vascular disease in diabetes
NJ Morrish et al.
DIABETOLOGIA (2001)
分享论文
